Show results for
Refine by
Drug Platform Suppliers Serving Mongolia
44 companies found
based inTaipei, TAIWAN
Lumosa Therapeutics is a clinical-stage pharmaceutical company dedicating to develop novel therapies and solutions for neurological and oncological diseases with urgent unmet medical need. Besides of using Lumosa's own technology platform in drug ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of ...
based inDessau-Rosslau, GERMANY
IDT Biologika is an international leader in the contract development and manufacture of Viral Vaccines, Viral Vectors for Gene and Immune Therapeutics, Oncolytic Viruses, Virus-Like Particles, and other biologics. We are a full-service biologics ...
As one of the world’s leading CDMOs for vaccines, gene and immune therapeutics, and other biologics, IDT Biologika has a wealth of experience in the biological processes and technologies used to produce Viral Vaccines, Viral Vectors, and ...
based inChicago, ILLINOIS (USA)
Our company began as Nymirum. As protein drug discovery continued to exhaust low-hanging fruits, we founded Nymirum in 2009 to tackle a new and challenging frontier filled with untapped therapeutic potential: targeting RNA with small molecules. We ...
Exploiting RNA dynamics: RNAs rapidly exchange between a vast array of distinct 3D conformations, each revealing potentially novel binding surfaces. These dynamics are critical to understanding RNA function and fully exploiting its untapped ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
based inEstuary Banks, UNITED KINGDOM
For over 35 years, Powder Systems Limited (PSL) has been at the forefront of designing and engineering advanced technology to support process development. We are a globally recognised, award-winning business with expertise in pharmaceutical and ...
The MSR™ MicroSphere Refiner is a cGMP piece of equipment that allows drug developers and manufacturers to complete a wide range of aseptic processes with their microspheres at various scales. It is a one-of-its-kind solution has been ...
based inNaples, FLORIDA (USA)
Enveric Biosciences is leveraging its discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
Filgotinib, a preferential JAK1 inhibitor, is marketed as Jyseleca in the European Union (incl. Norway), Great Britain, and Japan for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have responded ...
based inSonceboz-Sombeval, SWITZERLAND
SONCEBOZ SA is a company which has earned a global reputation for its mechatronic drive systems designed to meet the specific needs of its customers. We create, develop and produce high quality mechatronic systems. Designed for positioning, flow ...
Manual Reconstitution of lyophilized drug formulations is a complex procedure and challenging for patients and caregivers alike. The ARI automatically facilitates the mixing of diluent and lyophilized drug in a easy-to-use fashion without the need ...
based in, NEW JERSEY (USA)
Founded in 2013 by a group of passionate synthetic biologists with decades of industry experience and a proven track record of delivering cost-effective DNA solutions, Synbio Technologies is incorporated with a single mission in mind: to empower ...
Hybridoma technology features the effective usage of innate functions of both immune and cancer cells to generate monoclonal antibodies (mAbs). The resulting hybridoma cell lines are produced to combat specific antigens of interest. Such technology ...
based inBudapest, HUNGARY
Cytocast, an innovative TechBio startup located in Budapest, is at the forefront of data-driven medical technology.The company's primary focus is on integrating extensive multi-omics data with high-performance computing and advanced data science ...
Cytocast is at the forefront of medical technology with its innovative Cytocast Digital Twin Platform™, a pioneering solution in drug development and personalized medicine. At its core is the CYTOCAST DIGITAL ...
based inSan Clemente, CALIFORNIA (USA)
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. At Glaukos, our focus is to develop and lead the ...
based inColumbus, OHIO (USA)
Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and ...
based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic ...
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
based inThousand Oaks, CALIFORNIA (USA)
Amgen is one of the world™s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. Amgen is committed to ...
based inEugene, OREGON (USA)
InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome ...
based inNanjing, CHINA
Founded in July 2015, Triastek is dedicated to the mission of 'revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefitting patients worldwide.' We have created the Melt Extrusion Deposition (MED) 3D ...
based inOxford, UNITED KINGDOM
Founded in 2012, we are the leading pharmatech company and the first to automate drug discovery. As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our ...
based inSeongnam-si, SOUTH KOREA
Theramx Inc. was founded on the conviction that health, and the extension of life, is one of the important values that can be provided to humankind. Our company develops treatment platforms that provide the best diagnoses and treatments. As a ...
Drug delivery platform technology designed to maximize efficacy while simultaneously minimizing side effects of existing drugs by delivery to desired ...
based inBeach Drive, UNITED KINGDOM
Oval aims to bring truly patient-centric autoinjector platforms to market. Founded in 2009 by Matthew Young, Oval takes a different approach, designing from the outside in, ensuring that all patient needs are met. Our team has a wide range of ...
Oval’s philosophy is to design platforms to be customisable for specific patient needs. Going deeper than the immediate cognitive and physical need when delivering a drug, we look at each patient group’s ...